- Home
- BATL vs LPCN Comparison
BATL vs LPCN Comparison
Compare BATL & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- LPCN
- Stock Information
- Founded
- BATL 1987
- LPCN 1997
- Country
- BATL United States
- LPCN United States
- Employees
- BATL N/A
- LPCN N/A
- Industry
- BATL Oil & Gas Production
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- LPCN Health Care
- Exchange
- BATL Nasdaq
- LPCN Nasdaq
- Market Cap
- BATL 19.3M
- LPCN 16.1M
- IPO Year
- BATL N/A
- LPCN N/A
- Fundamental
- Price
- BATL $1.07
- LPCN $2.89
- Analyst Decision
- BATL
- LPCN Strong Buy
- Analyst Count
- BATL 0
- LPCN 2
- Target Price
- BATL N/A
- LPCN $9.00
- AVG Volume (30 Days)
- BATL 387.2K
- LPCN 16.1K
- Earning Date
- BATL 08-14-2025
- LPCN 11-06-2025
- Dividend Yield
- BATL N/A
- LPCN N/A
- EPS Growth
- BATL N/A
- LPCN N/A
- EPS
- BATL N/A
- LPCN N/A
- Revenue
- BATL $185,206,000.00
- LPCN $4,208,119.00
- Revenue This Year
- BATL N/A
- LPCN N/A
- Revenue Next Year
- BATL N/A
- LPCN N/A
- P/E Ratio
- BATL N/A
- LPCN N/A
- Revenue Growth
- BATL N/A
- LPCN N/A
- 52 Week Low
- BATL $1.02
- LPCN $2.68
- 52 Week High
- BATL $6.89
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- BATL 35.35
- LPCN 39.07
- Support Level
- BATL $1.02
- LPCN $2.86
- Resistance Level
- BATL $1.21
- LPCN $3.00
- Average True Range (ATR)
- BATL 0.09
- LPCN 0.12
- MACD
- BATL 0.00
- LPCN -0.01
- Stochastic Oscillator
- BATL 18.52
- LPCN 12.28
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.